| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | sphingosine N-acyltransferase activity | 4.66e-08 | 7 | 23 | 3 | GO:0050291 | |
| GeneOntologyMolecularFunction | N-acyltransferase activity | 2.13e-04 | 102 | 23 | 3 | GO:0016410 | |
| GeneOntologyMolecularFunction | acyltransferase activity, transferring groups other than amino-acyl groups | 2.48e-03 | 238 | 23 | 3 | GO:0016747 | |
| GeneOntologyBiologicalProcess | ceramide biosynthetic process | 6.24e-05 | 73 | 22 | 3 | GO:0046513 | |
| GeneOntologyBiologicalProcess | ceramide metabolic process | 2.29e-04 | 113 | 22 | 3 | GO:0006672 | |
| GeneOntologyBiologicalProcess | sphingolipid biosynthetic process | 2.53e-04 | 117 | 22 | 3 | GO:0030148 | |
| Domain | NPIP | 2.08e-09 | 14 | 24 | 4 | IPR009443 | |
| Domain | Lag1/Lac1 | 3.72e-08 | 6 | 24 | 3 | IPR016439 | |
| Domain | Homeobox | 4.04e-07 | 234 | 24 | 6 | PF00046 | |
| Domain | HOMEOBOX_1 | 4.25e-07 | 236 | 24 | 6 | PS00027 | |
| Domain | HOX | 4.36e-07 | 237 | 24 | 6 | SM00389 | |
| Domain | Homeobox_dom | 4.58e-07 | 239 | 24 | 6 | IPR001356 | |
| Domain | HOMEOBOX_2 | 4.58e-07 | 239 | 24 | 6 | PS50071 | |
| Domain | TLC | 1.03e-06 | 16 | 24 | 3 | PS50922 | |
| Domain | TLC-dom | 1.03e-06 | 16 | 24 | 3 | IPR006634 | |
| Domain | TLC | 1.03e-06 | 16 | 24 | 3 | SM00724 | |
| Domain | TRAM_LAG1_CLN8 | 1.03e-06 | 16 | 24 | 3 | PF03798 | |
| Domain | - | 1.23e-06 | 283 | 24 | 6 | 1.10.10.60 | |
| Domain | Homeodomain-like | 3.10e-06 | 332 | 24 | 6 | IPR009057 | |
| Domain | DH_1 | 2.95e-03 | 63 | 24 | 2 | PS00741 | |
| Domain | RhoGEF | 3.42e-03 | 68 | 24 | 2 | SM00325 | |
| Domain | HTH_motif | 3.52e-03 | 69 | 24 | 2 | IPR000047 | |
| Domain | DH_2 | 3.62e-03 | 70 | 24 | 2 | PS50010 | |
| Domain | RhoGEF | 3.62e-03 | 70 | 24 | 2 | PF00621 | |
| Domain | - | 3.73e-03 | 71 | 24 | 2 | 1.20.900.10 | |
| Domain | DH-domain | 3.73e-03 | 71 | 24 | 2 | IPR000219 | |
| Domain | PH_dom-like | 1.67e-02 | 426 | 24 | 3 | IPR011993 | |
| Pathway | WP_SYNTHESIS_OF_CERAMIDES_AND_1DEOXYCERAMIDES | 2.21e-06 | 22 | 17 | 3 | M45544 | |
| Pathway | WP_SPHINGOLIPID_METABOLISM_OVERVIEW | 3.30e-06 | 25 | 17 | 3 | MM15931 | |
| Pathway | WP_SPHINGOLIPID_METABOLISM_INTEGRATED_PATHWAY | 3.72e-06 | 26 | 17 | 3 | MM15892 | |
| Pathway | WP_SPHINGOLIPID_METABOLISM_INTEGRATED_PATHWAY | 3.72e-06 | 26 | 17 | 3 | M39784 | |
| Pathway | WP_SPHINGOLIPID_METABOLISM_OVERVIEW | 4.19e-06 | 27 | 17 | 3 | M39863 | |
| Pathway | REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS | 4.19e-06 | 27 | 17 | 3 | MM14646 | |
| Pathway | WP_SPHINGOLIPID_PATHWAY | 5.80e-06 | 30 | 17 | 3 | M39501 | |
| Pathway | REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS | 1.10e-05 | 37 | 17 | 3 | M554 | |
| Pathway | REACTOME_SPHINGOLIPID_METABOLISM | 1.71e-04 | 92 | 17 | 3 | MM15086 | |
| Pathway | REACTOME_SPHINGOLIPID_METABOLISM | 2.68e-04 | 107 | 17 | 3 | M14857 | |
| Pathway | REACTOME_EPHB_MEDIATED_FORWARD_SIGNALING | 8.89e-04 | 37 | 17 | 2 | MM15022 | |
| Pathway | REACTOME_EPHB_MEDIATED_FORWARD_SIGNALING | 1.15e-03 | 42 | 17 | 2 | M27308 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_DIFFERENTIATION | 2.56e-03 | 63 | 17 | 2 | M39366 | |
| Pathway | REACTOME_EPH_EPHRIN_SIGNALING | 2.72e-03 | 65 | 17 | 2 | MM14911 | |
| Pathway | REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING | 4.61e-03 | 85 | 17 | 2 | MM14746 | |
| Pathway | REACTOME_EPH_EPHRIN_SIGNALING | 5.38e-03 | 92 | 17 | 2 | M27201 | |
| Pathway | REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING | 5.96e-03 | 97 | 17 | 2 | M9400 | |
| Pubmed | 2.08e-09 | 4 | 29 | 3 | 12912983 | ||
| Pubmed | 2.08e-09 | 4 | 29 | 3 | 12297269 | ||
| Pubmed | 5.21e-09 | 5 | 29 | 3 | 26887952 | ||
| Pubmed | 1.04e-08 | 6 | 29 | 3 | 17977534 | ||
| Pubmed | 1.04e-08 | 6 | 29 | 3 | 23936132 | ||
| Pubmed | Ceramide synthesis regulates T cell activity and GVHD development. | 6.71e-07 | 2 | 29 | 2 | 28515365 | |
| Pubmed | 1.50e-06 | 27 | 29 | 3 | 23096701 | ||
| Pubmed | Morphology-based mammalian stem cell tests reveal potential developmental toxicity of donepezil. | 1.50e-06 | 27 | 29 | 3 | 25269881 | |
| Pubmed | Regulation of meiotic telomere dynamics through membrane fluidity promoted by AdipoR2-ELOVL2. | 1.88e-06 | 29 | 29 | 3 | 38485951 | |
| Pubmed | Divergent origins and concerted expansion of two segmental duplications on chromosome 16. | 2.01e-06 | 3 | 29 | 2 | 11948212 | |
| Pubmed | 4.02e-06 | 4 | 29 | 2 | 23538298 | ||
| Pubmed | Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. | 6.70e-06 | 5 | 29 | 2 | 15823095 | |
| Pubmed | 1.14e-04 | 19 | 29 | 2 | 18711365 | ||
| Pubmed | 1.53e-04 | 22 | 29 | 2 | 12812986 | ||
| Cytoband | 16p12.2 | 1.74e-06 | 37 | 29 | 3 | 16p12.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr16p12 | 1.76e-04 | 172 | 29 | 3 | chr16p12 | |
| Cytoband | 16p11.2 | 2.39e-04 | 191 | 29 | 3 | 16p11.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr16p11 | 7.14e-04 | 278 | 29 | 3 | chr16p11 | |
| Cytoband | 19p13.2 | 9.20e-03 | 229 | 29 | 2 | 19p13.2 | |
| GeneFamily | CERS class homeoboxes | 5.80e-09 | 6 | 13 | 3 | 530 | |
| GeneFamily | PRD class homeoboxes and pseudogenes | 1.93e-03 | 92 | 13 | 2 | 521 | |
| Coexpression | JINESH_BLEBBISHIELD_TRANSFORMED_STEM_CELL_SPHERES_DN | 1.86e-05 | 302 | 29 | 5 | M38975 | |
| Coexpression | JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP | 5.56e-05 | 380 | 29 | 5 | M38974 | |
| CoexpressionAtlas | Mesoderm Day 30-method_NA_vs_Mesoderm Day 30-method_plasmid-Confounder_removed-fold2.0_adjp0.05 | 7.71e-05 | 371 | 26 | 5 | PCBC_ratio_MESO-30_from-ESC_vs_MESO-30_from-plasmid_cfr-2X-p05 | |
| CoexpressionAtlas | Mesoderm Day 30-reprogram_NA_vs_Mesoderm Day 30-reprogram_OSKM - NLT-Confounder_removed-fold2.0_adjp0.05 | 7.71e-05 | 371 | 26 | 5 | PCBC_ratio_MESO-30_from-ESC_vs_MESO-30_from-OSKM - NLT_cfr-2X-p05 | |
| CoexpressionAtlas | MESO-30 blastocyst_vs_MESO-30 fibroblast-Confounder_removed-fold2.0_adjp0.05 | 7.71e-05 | 371 | 26 | 5 | PCBC_ratio_MESO-30 blastocyst_vs_MESO-30 fibroblast_cfr-2X-p05 | |
| ToppCell | severe-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.51e-07 | 193 | 29 | 5 | 9337bc93e3904c7fc7c93c328518bcd6453b1e8c | |
| ToppCell | mild-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.75e-07 | 199 | 29 | 5 | f0b0097df0026496470a80d8cc9375ffd8389b00 | |
| ToppCell | severe-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 7.77e-06 | 197 | 29 | 4 | 57ebd552f10d6278623b52a3d484d4b91ae1d028 | |
| ToppCell | mild-low-quality_cells|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 7.77e-06 | 197 | 29 | 4 | e4331969bd911d1ebb5453f40a7057297b5389b4 | |
| Computational | Neighborhood of ATM | 5.76e-04 | 30 | 13 | 2 | GNF2_ATM | |
| Disease | level of Sphingomyelin (d38:1) in blood serum | 2.95e-04 | 30 | 25 | 2 | OBA_2045180 | |
| Disease | fish consumption measurement | 1.35e-03 | 64 | 25 | 2 | EFO_0010139 | |
| Disease | Cleft palate, cleft lip | 1.65e-03 | 279 | 25 | 3 | EFO_0003959, HP_0000175 | |
| Disease | late-onset Alzheimers disease | 1.88e-03 | 292 | 25 | 3 | EFO_1001870 | |
| Disease | amino acid measurement | 2.38e-03 | 678 | 25 | 4 | EFO_0005134 | |
| Disease | attention deficit hyperactivity disorder, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia | 3.31e-03 | 101 | 25 | 2 | EFO_0003756, EFO_0003761, EFO_0003888, MONDO_0004985, MONDO_0005090 | |
| Disease | RS-10-hydroxywarfarin to RS-warfarin ratio measurement | 3.91e-03 | 110 | 25 | 2 | EFO_0803335 | |
| Disease | Drug Use Disorders | 4.26e-03 | 115 | 25 | 2 | C0013222 | |
| Disease | Drug Dependence | 4.26e-03 | 115 | 25 | 2 | C1510472 | |
| Disease | Drug habituation | 4.26e-03 | 115 | 25 | 2 | C0013170 | |
| Disease | Substance Dependence | 4.26e-03 | 115 | 25 | 2 | C0038580 | |
| Disease | Substance Use Disorders | 4.26e-03 | 115 | 25 | 2 | C0038586 | |
| Disease | Substance-Related Disorders | 4.26e-03 | 115 | 25 | 2 | C0236969 | |
| Disease | Drug abuse | 4.26e-03 | 115 | 25 | 2 | C0013146 | |
| Disease | Organic Mental Disorders, Substance-Induced | 4.26e-03 | 115 | 25 | 2 | C0029231 | |
| Disease | Prescription Drug Abuse | 4.26e-03 | 115 | 25 | 2 | C4316881 | |
| Disease | mean reticulocyte volume | 4.29e-03 | 799 | 25 | 4 | EFO_0010701 | |
| Disease | Substance abuse problem | 4.33e-03 | 116 | 25 | 2 | C0740858 | |
| Disease | sleep quality | 4.48e-03 | 118 | 25 | 2 | EFO_0005272 | |
| Disease | bipolar I disorder | 6.33e-03 | 141 | 25 | 2 | EFO_0009963 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LQQTQRWFRRRRNQD | 111 | Q9HA82 | |
| NQRRSRQWENRFIAL | 311 | Q6ZS30 | |
| TDVQQRAWRSNRRRQ | 101 | Q92617 | |
| TDVQQRAWRSNRRRQ | 101 | F8W0I5 | |
| QRRWLRRCEQQQRAQ | 1451 | Q8N1W1 | |
| FRRRWRLNFNRQQPT | 381 | Q96FE5 | |
| TDVQQRAWRSNRRRQ | 101 | A8MRT5 | |
| TDVQQRAWRSNRRRQ | 101 | C9JG80 | |
| TDVQQRAWRSNRSRQ | 101 | A6NHN6 | |
| TDVQQRAWRSNRRRQ | 101 | E5RHQ5 | |
| RQVERWFRSRRNQER | 111 | Q8IU89 | |
| LERQRQLEWERNRRQ | 441 | Q15811 | |
| RSIQRWFRQRRNQEK | 111 | Q6ZMG9 | |
| RRVFTNSRERWRQQN | 151 | P12980 | |
| QIWFQNRRSRLLLQR | 146 | A6NLW8 | |
| TDVQQRAWRSNRRRQ | 101 | A6NJU9 | |
| QWRQQLAARRQEQRA | 826 | A8K8P3 | |
| SNQWQGVIRRAQQRR | 7541 | Q8NF91 | |
| QRRARRQSQFNEVNQ | 126 | Q8WWF3 | |
| TQRQRRCRGQRWTVQ | 76 | Q9H633 | |
| QVSNWFKNRRQRDRN | 266 | Q9UIU6 | |
| QLQRARLQQFFRRRN | 56 | Q9Y228 | |
| QRLQGREANWRQTRR | 36 | Q2QL34 | |
| ERWQQEQEQRRRSRA | 151 | Q96SI1 | |
| QRAVRQAWAREQQRL | 2696 | Q6N022 | |
| ARQREQEARLRQQWE | 21 | Q9BT92 | |
| ARIQVWFQNRRAKQR | 111 | O75360 | |
| RQNNQIRRWSSAQAR | 2321 | Q9UPU5 | |
| EWDRQNARLRQENAR | 81 | Q2TAM9 |